Clinical Trials
7 trialsNCT07472153 2026-05-28
PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer
N.N. Alexandrov National Cancer Centre
Phase 2/3 Recruiting
NCT07602140 2026-05-22
TACE Combined With Thermal Ablation and ADC, PD-1, and Chemotherapy as First-line Treatment for HER2-highly-expressing Gastric Cancer With Liver Metastases: A Multicenter, Single-arm Prospective Clinical Study.
Shandong Provincial Hospital
Phase 2 Not yet recruiting
NCT07333287 2026-01-12
A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With Arterial Infusion Chemotherapy and Embolization Combined With Dual Immune Checkpoint Inhibitors.
Shandong Provincial Hospital
Phase 2 Not yet recruiting
NCT06709859 2025-07-17
Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC
Shandong Public Health Clinical Center
Phase 2 Recruiting
NCT07069270 2025-07-16
A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT06617936 2025-07-15
Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.
Shandong Public Health Clinical Center
Phase 2 Recruiting
NCT06602063 2025-06-27
Surgery for Relapsed Ovarian Cancer in Precision
Shanghai Gynecologic Oncology Group
Phase 1/2 Not yet recruiting